FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas
1999
FasL Expression in Liver Metastases of Colorectal Cancer
Sample size: 21
publication
Evidence: moderate
Author Information
Author(s): Mann B, Gratchev A, Böhm C, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Hanski C
Primary Institution: Universitätsklinikum Benjamin Franklin
Hypothesis
Colorectal carcinoma cells express Fas ligand (FasL) to evade immune response by inducing apoptosis in tumor-infiltrating lymphocytes.
Conclusion
Metastasizing colorectal tumor cells express FasL more frequently than primary tumors, potentially aiding in immune evasion.
Supporting Evidence
- FasL was detected in 30-40% of primary tumors and 60-100% of metastases.
- The amount of activated TILs was lower in metastases than in primary tumors in 90% of patients.
Takeaway
This study found that cancer cells in liver metastases have a special protein that helps them avoid being attacked by the body's immune system.
Methodology
The study analyzed FasL mRNA and protein expression in paired tissue samples from patients using four different methods.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website